リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study

Kumabe, Ayako Kenzaka, Tsuneaki Yahata, Shinsuke Goda, Ken Okayama, Masanobu 神戸大学

2022.10

概要

This study aimed to investigate the influence of sex, age, and quadrivalent vaccination history on adverse reactions (ARs) to influenza vaccines and the relationship between the occurrence of ARs and the risk of influenza infection. Study participants were employees of three hospitals in the Hyogo Prefecture, Japan, who received the influenza vaccine in 2019. Data were collected using questionnaires. The main factors were age, sex, and history of influenza vaccination as a control. The primary outcomes were the incidence of local and systemic ARs attributable to the vaccine and positive influenza cases among the participants during the influenza season. Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI). Among the 1493 participants, 80% experienced either local or systemic ARs. ARs were less common among men than among women (OR: 0.28, 95% CI: 0.21–0.37) and less common among those aged ≥60 years (OR: 0.48, 95% CI: 0.26–0.89). ARs were significantly more likely to occur in those with a history of influenza vaccination (OR: 1.96, 95% CI: 1.15–3.33). Those who had ARs, notably localized ones, were significantly more likely to incur influenza infection. Individuals who report ARs to influenza vaccination should strictly adopt non-pharmaceutical preventive measures in the hospital, community settings, and at home.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020. China CDC Wkly. 2020, 2, 113–122. [CrossRef]

2. National Institute of Infectious Diseases. Infectious Agents Surveillance Report (IASR). Influenza 2020/21 Season. IASR; Volume 42. pp. 239–241. Available online: https://www.niid.go.jp//niid/ja/flu-m/flu-iasrtpc/10780-501t.html (accessed on 11 August 2022). (In Japanese)

3. National Institute of Infectious Diseases. Infectious Agents Surveillance Report (IASR). Influenza 2019/20 Season. IASR; Volume 41. pp. 191–193. Available online: https://www.niid.go.jp/niid/ja/flu-m/flu-iasrtpc/9961-489t.html (accessed on 11 August 2022). (In Japanese)

4. Available online: https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai21/dl/h6.pdf (accessed on 11 August 2022). (In Japanese)

5. Ishida, T.; Seki, M.; Oishi, K.; Tateda, K.; Fujita, J.; Kadota, J.I.; Kawana, A.; Izumikawa, K.; Kikuchi, T.; Ohmagari, N.; et al. Clinical manifestations of adult patients requiring influenza-associated hospitalization: A prospective multicenter cohort study in Japan via internet surveillance. J. Infect. Chemother. 2021, 27, 480–485. [CrossRef]

6. Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L.J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289, 179–186. [CrossRef] [PubMed]

7. Goodwin, K.; Viboud, C.; Simonsen, L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006, 24, 1159–1169. [CrossRef] [PubMed]

8. Seki, Y.; Onose, A.; Murayama, T.; Koide, C.; Sugaya, N. Influenza vaccine showed a good preventive effect against influenza- associated hospitalization among elderly patients, during the 2016/17 season in Japan. J. Infect. Chemother. 2018, 24, 873–880. [CrossRef] [PubMed]

9. Who Recommended Composition of Influenza Virus Vaccines: Recommended Composition of Influenza Virus Vaccines for Use in the 2013–2014 Northern Hemisphere Influenza Season. Available online: https://www.who.int/publications/m/item/ recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2013-2014-northern-hemisphere-influenza-season (ac- cessed on 30 October 2021).

10. Watanabe, K.; Matsumoto, S.; Toyoshima, E.; Ishigami, K.; Ohsaki, Y. Adverse drug reaction following quadrivalent influenza vaccination coverage of health care workers. Jpn. J. Environ. Infect. 2016, 31, 397–401. [CrossRef]

11. Ito, S.; Morioka, Y.; Haze, K.; Kambayashi, H.; Hara, T. Outcome study on “Alepanrix (HlN1)”. Pharma Medica. 2013, 31, 135–140.

12. Cadorna-Carlos, J.B.; Nolan, T.; Borja-Tabora, C.F.; Santos, J.; Montalban, M.C.; de Looze, F.J.; Eizenberg, P.; Hall, S.; Dupuy, M.; Hutagalung, Y.; et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine 2015, 33, 2485–2492. [CrossRef] [PubMed]

13. Aspinall, R.; Del Giudice, G.; Effros, R.B.; Grubeck-Loebenstein, B.; Sambhara, S. Challenges for vaccination in the elderly. Immun. Ageing 2007, 4, 1–9. [CrossRef] [PubMed]

14. Targonski, P.V.; Jacobson, R.M.; Poland, G.A. Immunosenescence: Role and measurement in influenza vaccine response among the elderly. Vaccine 2007, 25, 3066–3069. [CrossRef]

15. Klein, S.L.; Marriott, I.; Fish, E.N. Sex-based differences in immune function and responses to vaccination. Trans. R Soc. Trop. Med. Hyg. 2015, 109, 9–15. [CrossRef]

16. Izumo, T.; Kuse, N.; Awano, N.; Tone, M.; Sakamoto, K.; Takada, K.; Muto, Y.; Fujimoto, K.; Saiki, A.; Ito, Y.; et al. Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan. Respir. Investig. 2021, 59, 635–642. [CrossRef] [PubMed]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る